Ligand Pharmaceuticals IncorporatedLGNDNASDAQ
Loading
EBITDA Margin Over TimeContracting
Percentile Rank79
3Y CAGR+20.9%
5Y CAGR+16.1%
Year-over-Year Change
EBITDA as a percentage of revenue
3Y CAGR
+20.9%/yr
vs -18.7%/yr prior
5Y CAGR
+16.1%/yr
Recent acceleration
Acceleration
+39.6pp
Accelerating
Percentile
P79
Within normal range
vs 5Y Ago
2.1x
Strong expansion
Streak
1 yr
Consecutive growthContracting
| Period | Value | YoY Change |
|---|---|---|
| TTM | 73.11% | +199.5% |
| 2024 | 24.41% | -68.2% |
| 2023 | 76.79% | +85.6% |
| 2022 | 41.38% | -30.0% |
| 2021 | 59.11% | +70.6% |
| 2020 | 34.65% | -95.2% |
| 2019 | 728.38% | +668.6% |
| 2018 | 94.77% | +64.8% |
| 2017 | 57.51% | +13.6% |
| 2016 | 50.63% | - |